<DOC>
	<DOCNO>NCT02845609</DOCNO>
	<brief_summary>Sialic Acid-Extended Release ( SA-ER , aceneuramic acid , UX001 ) extend release formulation sialic acid ( SA , also know N-acetylneuraminic acid NANA ) . The SA-ER currently study substrate replacement therapy patient GNE myopathy . The investigator plan study SA-ER compound cohort five patient GNE-related thrombocytopenia .</brief_summary>
	<brief_title>Efficacy Sialic Acid GNE Related Thrombocytopenia</brief_title>
	<detailed_description>The investigator identify 5 affected individual ( 3 male 2 female three family , age 19-40 year ) GNE-related thrombocytopenia . All subject receive 2 gram SA-ER , three time per day total daily dose 6 gram ( 6,000 mg ) . The dose administer food ( i.e . within 30 minute meal snack ) . Efficacy evaluate improvement clinical laboratory assessment . Results Baseline assessment compare post-treatment assessment efficacy conclusion base improvement Baseline last scheduled assessment . Safety evaluate incidence frequency adverse event , include clinically significant change Baseline schedule time point : - Vital sign . - History physical examination finding . - Laboratory evaluation . - Serum uric acid level urinary excretion uric acid .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Patients GNErelated macrothrombocytopenia investigate family non consent study pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Congenital macrothrombocytopenia</keyword>
	<keyword>Sialic acid</keyword>
	<keyword>Bleeding</keyword>
</DOC>